Royce & Associates’s Castle Biosciences CSTL Stock Holding History

Royce & Associates’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.11M	Buy	+59,513	New	+$1.8M	0.02%	611
2024 Q3	–	Sell	-15,365	Closed	-$334K	–	872
2024 Q2	$334K	Buy	15,365 +4,240	+38%	+$94.5K	﹤0.01%	818
2024 Q1	$246K	Sell	11,125 -20,517	-65%	-$446K	﹤0.01%	821
2023 Q4	$683K	Buy	31,642 +8,833	+39%	+$155K	0.01%	768
2023 Q3	$385K	Buy	+22,809	New	+$399K	﹤0.01%	833
2021 Q1	–	Sell	-35,000	Closed	-$2.35M	–	1021
2020 Q4	$2.35M	Sell	35,000 -481	-1%	-$26.1K	0.02%	693
2020 Q3	$1.82M	Buy	35,481 +6,481	+22%	+$288K	0.02%	695
2020 Q2	$1.09M	Buy	+29,000	New	+$991K	0.01%	761

Other funds holding CSTL

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Royce & Associates's CSTL Position: Q3 2026 in Review

Royce & Associates opened a new position in Castle Biosciences (CSTL) in Q3 2026: 59,513 shares worth $2.11M. The stake represents 0.02% of the portfolio and ranks #611 among its holdings. This is a return to the name: Royce & Associates previously reported a position in CSTL as recently as Q2 2024.

Royce & Associates first reported a position in CSTL in Q2 2020 and has held it in 8 quarters since. The position peaked at $2.35M in Q4 2020. 76 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Royce & Associates held 59,513 shares of Castle Biosciences worth $2.11M as of Q3 2026.
Castle Biosciences was a new Royce & Associates position in Q3 2026.
Castle Biosciences made up 0.02% of Royce & Associates's portfolio in Q3 2026, its #611 holding.
Royce & Associates first reported a position in Castle Biosciences in Q2 2020 and has held it in 8 quarters since.
Royce & Associates's Castle Biosciences position peaked at $2.35M in Q4 2020.
76 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Royce & Associates's 13F filing for Q3 2026, filed 9 Nov 2026.